title: HGF mediates the anti-inflammatory effects of PRP on injured tendons.
abstract: Platelet-rich plasma (PRP) containing hepatocyte growth factor (HGF) and other growth factors are widely used in orthopaedic/sports medicine to repair injured tendons. While PRP treatment is reported to decrease pain in patients with tendon injury, the mechanism of this effect is not clear. Tendon pain is often associated with tendon inflammation, and HGF is known to protect tissues from inflammatory damages. Therefore, we hypothesized that HGF in PRP causes the anti-inflammatory effects. To test this hypothesis, we performed in vitro experiments on rabbit tendon cells and in vivo experiments on a mouse Achilles tendon injury model. We found that addition of PRP or HGF decreased gene expression of COX-1, COX-2, and mPGES-1, induced by the treatment of tendon cells in vitro with IL-1β. Further, the treatment of tendon cell cultures with HGF antibodies reduced the suppressive effects of PRP or HGF on IL-1β-induced COX-1, COX-2, and mPGES-1 gene expressions. Treatment with PRP or HGF almost completely blocked the cellular production of PGE2 and the expression of COX proteins. Finally, injection of PRP or HGF into wounded mouse Achilles tendons in vivo decreased PGE2 production in the tendinous tissues. Injection of platelet-poor plasma (PPP) however, did not reduce PGE2 levels in the wounded tendons, but the injection of HGF antibody inhibited the effects of PRP and HGF. Further, injection of PRP or HGF also decreased COX-1 and COX-2 proteins. These results indicate that PRP exerts anti-inflammatory effects on injured tendons through HGF. This study provides basic scientific evidence to support the use of PRP to treat injured tendons because PRP can reduce inflammation and thereby reduce the associated pain caused by high levels of PGE2.
authors.affiliation: MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Jianying
authors.initials: J
authors.lastname: Zhang
authors.forename: Kellie K
authors.initials: KK
authors.lastname: Middleton
authors.forename: Freddie H
authors.initials: FH
authors.lastname: Fu
authors.forename: Hee-Jeong
authors.initials: HJ
authors.lastname: Im
authors.forename: James H-C
authors.initials: JH
authors.lastname: Wang
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D002478:Cells, Cultured; D051545:Cyclooxygenase 1 / Q000235:genetics / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D005260:Female; D015870:Gene Expression; D017228:Hepatocyte Growth Factor / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000502:physiology; D051379:Mice; D053657:Platelet-Rich Plasma / Q000502:physiology*; D011817:Rabbits; D052256:Tendinopathy / Q000628:therapy; D013708:Tendon Injuries / Q000473:pathology / Q000628:therapy*; D013710:Tendons / Q000378:metabolism / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators; D017228:Hepatocyte Growth Factor; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D015232:Dinoprostone